Kornimate/medical-research-clean huggingface dataset:
hemoglobinopathy nursing program and pediatric nursing students

Conditions: Hemoglobinopathies; Thalassemia; Sickle Cell Disease; Nurse's Role

Summary: hemoglobinopathies are the most common life threatening, monogenic disorders in the world. the most common causes of hemoglobinopathies are sickle cell disease and thalassemia. aim: this study aimed to evaluate the effect of a hemoglobinopathy nursing program on pediatric nursing students' performance.


Eligibility criteria:
inclusion criteria: * pediatric nursing students registered for the academic year 2016/2017 exclusion criteria: * any student had personal or family history of hemoglobinopathies
treatment of rapid onset obesity, hypoventilation, hypothalamic dysfunction, and autonomic dysregulation (rohhad )

Conditions: ROHHAD Syndrome

Summary: rohhad (rapid onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation) syndrome is a rare pediatric disorder associated with a cancer called neuroblastoma and presumed to be driven by an attack of the immune system on specific area in the brain. patients develop severe symptoms and often succumb to this disease. based on the researchers' experience the investigators conduct a clinical trial to study intensive immunosuppression with high-dose cyclophosphamide in these patients. in addition to describing the symptomatic improvement, the investigators' trial seeks to define objective markers of disease activity.

baseline evaluation will include: sleep study and pulmonary evaluation hormone levels determination of up to 6 key rohhad-related symptoms to be followed hyperphagia questionnaire 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose (fdg) positron emission tomography (pet) scan dual energy x-ray absorptiometry (dxa) scan cerebrospinal fluid (csf) analysis patients will be treated with cyclophosphamide, 50 mg/kg (ideal body weight)/dose daily for 4 days, with mesna and hydration as prophylaxis against hemorrhagic cystitis. supportive care will include mucosal care, transfusions, infection prophylaxis, and empiric treatment for febrile neutropenia. composite severity score will be assessed to measure response of key symptoms, and formal neuropsychological testing, sleep study, and hormone studies will be performed.

Eligibility criteria:
inclusion criteria: * diagnosis of rohhad syndrome confirmed by two physicians. * any symptomatic improvement in response to a course of rituximab (five weekly doses) as assessed by parents and/or treating physician * normal brain mri * cared for at home by the family * patients requiring bilevel positive airway pressure (bipap) support are eligible * negative pregnancy test for post pubertal female patients exclusion criteria: * cardiac ejection fraction \<40% or shortening fraction \<20%. * inadequate pulmonary function, i.e. forced vital capacity or forced expiratory volume at one second \< 50% of predicted for children greater than 8 years of age, or oxygen saturation \<93% on pulse oximetry for younger children. * ventilator dependent * known chromosomal abnormality * active cancer diagnosis. neuroblastoma that requires only follow up is eligible. * pregnancy
expanded access program for idebenone in patients with leber's hereditary optic neuropathy who completed the leros study

Conditions: Leber's Hereditary Optic Neuropathy

Summary: expanded access program for idebenone in patients with leber's hereditary optic neuropathy who completed the leros study

see above

Eligibility criteria:
inclusion criteria: * patients who completed the leros study, who attended the end of study visit in leros and who in the opinion of investigator could benefit from continuation of idebenone treatment. * signed and dated informed consent form (to be obtained at the enrollment visit from patient or parent/legal guardian (if applicable) prior to dispensing idebenone to the patient). exclusion criteria: * patients who, in the opinion of the leros investigator, had unacceptable tolerability of idebenone treatment in leros trial. * patients who prematurely discontinued the leros study.
analyzing gait parameters among women with and without stress urinary incontinence

Conditions: Gait; Stress Urinary Incontinence; Women

Summary: this study will contribute to the existing body of knowledge on stress urinary incontinence and its impact on gait. the findings may have implications for the development of targeted interventions and rehabilitation strategies to improve mobility and quality of life in women with stress urinary incontinence

use the provided software or tools to analyze the recorded data, including (cadence, velocity, swing, and double limb support, stride time, step length, and stride length) of gait. the software measures the cadence as total number of steps per minute, and it measures the stride time as the time (in sec) from heel strike of one limb to the next heel strike of the same limb. also, the software measures the duration of stance, swing, and double limb support as percentage of stride time. also, the software measures the step and stride length (in cm).

Eligibility criteria:
inclusion criteria: * age between 40-60 years old. * women with bmi ≥30. * women are free from any other gynecological disorders or symptoms that may affect the results of the study. * all participants who will be enrolled in the study sign the informed consent form. * all participants will be of multiparas. * all participants will be diagnosed with a mild degree of stress urinary incontinence. exclusion criteria: * pregnancy * neurological disorders: such as parkinson's disease , multiple sclerosis, or any neurological dysfunction that may affect the gait parameters * musculoskeletal disorders: such as severe osteoarthritis or lower limb amputations * significant cognitive impairment: or dementia * previous pelvic surgery as pelvic organ prolapse repair or anti-incontinence procedures. * other significant medical conditions that could affect gait include severe cardiovascular disease or severe respiratory conditions. * walking pain.
effect of applying cognitive defusion techniques on mindful awareness, cognitive fusion and believability of delusions among clients with schizophrenia

Conditions: Schizophrenia; Psychosis; Nurse's Role; Delusions

Summary: schizophrenia causes hallucinations, delusions, and disorganized thinking, resulting in decreased functioning and lifelong therapy.delusion believability is the degree of belief in the truth of one's subjective experiences as representations of reality. it was unpleasant, typically accompanied by a suspicious, strange tension. delusional belief is seen as a means of resolving tension and conflict in cognition and experience. previous studies have shown that cognitive defusion strategies help people become more aware of their surroundings, accept their thoughts and feelings, and become more psychologically adjustable. defusion is crucial in reducing medication-resistant psychotic symptoms such delusions in schizophrenia patients. therefore, this study aimed to investigate the effects of cognitive defusion techniques on psychological flexibility, mindful awareness, cognitive fusion, and believability of delusions among clients with schizophrenia. research hypothesizes * clients who participated in cognitive defusion techniques had more psychological flexibility and mindful awareness than the control group. * clients who participated in cognitive defusion techniques had less cognitive fusion and delusional believability than the control group.


Eligibility criteria:
inclusion criteria: * male clients diagnosed with schizophrenia according to the dsm-v * diagnosed with schizophrenia with no comorbidity. * able to communicate coherently and relevantly. * able to read and write. * willing to participate in the study * duration of illness not exceeding 10 years. exclusion criteria: • any client in an acute phase or have any neurological disorder that may affect cognitive function were excluded from a study.

Keywords: believability of delusions cognitive defusion techniques cognitive fusion mindful awareness schizophrenia
application and effect evaluation of integrated nursing and medical management in pediatric lobar pneumonia

Conditions: Pediatrics; Lobar Pneumonia; Inflammatory Markers; Satisfaction

Summary: integrated nursing and medical management significantly improves clinical symptoms and pulmonary function in children with lobar pneumonia, shortens hospitalization duration, reduces complication rates, and enhances caregiver satisfaction. these findings support its broad clinical applicability and value.

this study aims to evaluate the clinical efficacy of integrated nursing and medical management in the treatment of pediatric lobar pneumonia. specifically, it assesses its impact on symptom relief, pulmonary function recovery, inflammatory response control, duration of hospitalization, and caregiver satisfaction. fifty pediatric patients diagnosed with lobar pneumonia and admitted to our hospital between january and december 2023 were selected and randomly assigned to either the observation group or the control group (n = 25 each) using a random number table. the control group received routine nursing care, while the observation group was additionally managed with an integrated nursing and medical approach. the two groups were compared in terms of duration of fever, cough, pulmonary rales, antibiotic treatment, length of hospital stay, pulmonary function parameters (fev₁, fvc, fev₁/fvc), inflammatory markers (crp, wbc, pct, ldh), overall treatment efficacy, caregiver satisfaction, and incidence of adverse events.

Eligibility criteria:
inclusion criteria: * (1) met the diagnostic criteria for lobar pneumonia, presenting with symptoms such as fever, cough, and pulmonary rales, and confirmed by laboratory tests and chest x-ray; * (2) aged between 1 and 12 years; * (3) informed consent was obtained from the child's legal guardians. exclusion criteria: * (1)presence of other concurrent respiratory diseases; * (2) congenital or acquired airway malformations, or airway foreign bodies; * (3) impaired hepatic or renal function; * (4) presence of other systemic diseases; * (5) cognitive impairment.
intense pulsed light in meibomian gland dysfunction

Conditions: Meibomian Gland Dysfunction

Summary: meibomian gland dysfunction (mgd) is a major cause of dry eye disease (ded). up to 86% of patients suffering from ded also show signs of mgd. traditional treatment of mgd is based on eye lid hygiene and massage in combination with intensive usage of lubricants. recently, a novel technology the intense pulsed light (ipl) therapy was introduced, which shows promising results in patients with meibomian gland dysfunction. originating from field of dermatology, subjecting improvement of dry eye symptoms was recognized after the treatment of facial rosacea using ipl. different hypotheses exist how ipl treatment might improve the situation in the dry eye patient. warming of the eyelid, due to the light application and reduction of bacterial load are two possible mode of actions. further, the used wavelengths in ipl may be modified that the light is only absorbed by oxygenated haemoglobin, which lead to an obliteration of telangiectasia and reduced inflammation on the lid margin. this principal is applied in the treatment of facial rosacea. aim of this study is to investigate the effect of ipl therapy in patients with mgd on dry eye parameters as well as subjective complaints.


Eligibility criteria:
inclusion criteria: * age older than 18 years * presence of meibomian gland dysfunction at any stage * presence of meibomian glands on each lower eyelid's meibography exclusion criteria: * fitzpatrick skin type vi * usage of eye drops other than lubricants (e.g. antibiotics, steroids, cyclosporin-a) * usage of systemic antibiotic therapy * any pathology of the ocular surface except dry eye disease (e.g. corneal scarring, cornea ectasia) * ocular surgery within prior 3 months * ocular injury within prior 3 months * ocular herpes of eye or eyelid within prior 3 months * active ocular infection * active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months * eyelid abnormalities that affect lid function * ocular surface abnormality that may compromise corneal integrity * pregnancy
ket-ro plus ro dbt for treatment resistant depression

Conditions: Treatment Resistant Depression

Summary: this pilot study will assess the safety and feasibility of intravenous (iv) ketamine combined with ro dbt in young adults with treatment-resistant depression (trd). in addition, this study will develop and utilize innovative methodological approaches to demonstrate the feasibility of precision medicine with this type of therapy.


Eligibility criteria:
inclusion criteria: * males and females aged 18-65 * moderate to severe persistent depression \[treatment resistant depression - trd\] (exhibiting 2+ unipolar major depression episodes (non-delusional) with prior treatment non-response to antidepressant or psychosocial treatment * treatment-resistant depression: defined as unipolar major depressive disorder, non-delusional (diagnosed by scid-5, structured clinical interview for the dsm ) that persists despite ≥ 2 adequate antidepressant trials of different classes in the current episode; including at least one evidence-based second-line treatment in the current episode (including serotonin norepinephrine reuptake inhibitors, bupropion, tricyclics, monoamine oxidase inhibitors, or augmentation with an atypical antipsychotic, stimulant, bupropion, lithium, or triiodothyroinine) higher proportion of oc (over controlled) words endorsed compared to uc (under controlled) words on the word pairs checklist * no current or past psychosis * english speaking * able to attend in-person behavioral sessions and ketamine/therapy visits * willingness to have ro dbt-a as only psychosocial treatment engaged in (medication treatment may continue-but see below for exclusion) exclusion criteria: * outside age range * significant neurological condition (i.e., seizure, stroke, severe head injury) or mental retardation (iq\<70) * current or recent substance use disorder, actively suicidal or homicidal (e.g., requires hospitalization) * use of naltrexone, memantine or medication considered contraindicated with ketamine * baseline systolic bp \> 150 systolic or 90 diastolic at evaluation. participants who initially present with elevated blood pressure may be re-assessed; and if needed, referred to their healthcare provider for hypertension management * taking more than 2 adequately-dosed oral antidepressants * inability to understand, speak and read english sufficiently * not be pregnant or at risk of becoming pregnant * medical conditions or medication usage that in the judgement of the investigators puts the patient at unreasonable safety risk * first degree relative with a psychotic diagnosis involving hallucinations, delusions, or disorganized thinking and speech (e.g. schizophrenia, schizoaffective disorder, etc)
dry needling in patients who had experience stroke

Conditions: Stroke

Summary: individuals who had experience a stroke usually suffer from spasticity at medium and long-terms. the presence of spasticity in the lower extremity implies several impairments for standing and walking inducing high disability. a recent study has proposed the use of dry needling for improving spasticity in the lower extremity. no study has investigated the effects of deep dry needling inserted into spastic musculature in stabilometry and moto function in patients who had experience a stroke. a randomized controlled trial investigating the effects of the inclusion of deep dry needling into a bobath interventional program on spasticity, motor function and balance (stabilometry) in individuals who had experience a stroke


Eligibility criteria:
inclusion criteria: * first-ever unilateral stroke; * hemiplegia resulting from stroke; * unilateral equinovarus gait with independent walk; * able to ambulate without supporting devices exclusion criteria: * recurrent stroke; * previous treatment with nerve blocks, motor point injections with neurolytic agents for spasticity at any time, or with btx-a in the previous 6 months * not independent in the basic activities of daily living * cognitive deficits; * progressive or severe neurologic diseases; * fear to needles; * any contraindication for dry needling

Keywords: stroke dry needling spasticity motor function stabilometry
the swoar trial sparing of swallowing and aspiration related organs at risk & submandibular gland with intensity modulated radiotherapy versus standard imrt in head and neck squamous cell carcinomas

Conditions: Head and Neck Neoplasms; Swallowing Sparing IMRT

Summary: the aim of swoar trial is to test sparing of dysphagia/ aspiration risk structures (dars) and contra lateral submandibular gland by imrt. hnscc of the oropharynx, larynx and the hypopharynx treated with radical concurrent chemoradiotherapy or radiotherapy will be included in the trial. patients will be randomized to swoar imrt or standard imrt. swallowing function will be evaluated the md anderson dysphagia inventory (mdadi) scoring. difference in the mean composite score of mdadi, a patient-reported outcome, at 6 months post radiotherapy is the primary outcome of the trial. secondary objectives include longitudinal assessment of aspiration prevention as evaluated by fees by the 8 point penetration-aspiration score. swallowing function, will be assessed by using the mdadi at baseline, at completion of crt/rt, 3, 6, 12, and 24 months. assessment of acute and late toxicity assessed at baseline, weekly during radiotherapy and then at 3, 6, 12, and 24 months post treatment as per rtog and lent soma score, respectively. treatment outcomes will be assessed in terms of loco-regional tumor recurrence and overall survival, assessed at follow-up visits 3, 6, 12, and 24 months post treatment and then annually until 5 years post treatment.


Eligibility criteria:
inclusion criteria: 1. aged 18 or above and less than 70 years 2. patient undergoing radiotherapy for hnscc of the oropharynx or larynx or hypopharynx. 3. stage t1-4, n0-3, m0 disease with histologically confirmed squamous cell carcinoma requiring bilateral neck radiotherapy and where sparing of contra lateral or one submandibular gland is possible 4. radiotherapy with concomitant chemotherapy (unless contraindicated) is the planned treatment 5. karnofsky performance score greater or equal 70 6. available to attend long term follow- up; 7. ability to complete the md anderson dysphagia inventory (mdadi) and eortc quality of life questionnaires english or hindi version. 8. willingness to undergo fees. 9. written informed consent for treatment. 10. available to attend long term follow- up exclusion criteria: 1. early carcinoma glottis (t1-t2, n0m0) 2. metastatic disease. 3. previous radiotherapy to the head and neck region 4. lateralised tumours, requiring unilateral irradiation 5. patients requiring radiation to both submandibular glands 6. evidence of pre-existing swallowing dysfunction (not related to hnc); 7. major head and neck surgery (excluding biopsies/tonsillectomy); 8. tracheostomy placement 9. previous or concurrent illness, which in the investigator's opinion would interfere with completion of therapy, trial assessments or follow-up 10. any invasive malignancy within previous 2 years (other than non melanomatous skin carcinoma or cervical carcinoma in situ).

Keywords: imrt dysphagia aspiration head and neck cancer radiation
effect of aspirin on hemostatic and vascular function after live fire fighting

Conditions: Cardiovascular Risk Factor; C.Medical Procedure; Vascular, Functional or Late; Electrolyte and Fluid Balance Conditions

Summary: the investigators hypothesize that 1. an acute treatment of low-dose aspirin will lead to a) decreased resting platelet activation, platelet aggregation, and clotting potential, b) increased fibrinolytic potential following fire fighting, c) no significant effect on endothelial function or arterial stiffness versus the placebo condition. 2. chronic treatment with low-dose aspirin will lead to a) decreased resting and fire fighting induced platelet activation, platelet aggregation, clotting potential, b) increased fibrinolytic potential, and c) increased endothelial function and decreased arterial stiffness in response to live fire fighting versus the placebo condition. 3. short-term fire fighting activity will result in: a) a reduction in arterial function (reduced endothelial function, increased augmentation index and an attenuated arterial stiffness response); b) a disruption in hemostasis that is characterized by an increase in platelet number and function, an increased coagulatory potential and altered fibrinolytic potential; and c) an elevation in procoagulatory cytokines, systemic inflammation, monokine chemoattractant protein, and matrix metalloproteinases.


Eligibility criteria:
inclusion criteria: * male firefighters (career and volunteer), medically cleared by home fire department. * ages 40 - 60 * completion of a yearly period medical evaluation based on nfpa 1582 within the past 12 months or an evaluation by an occupational medical group through this study. exclusion criteria: * over 60 or under 40 years of age. * not a firefighter. * individuals at risk for developing gastrointestinal (gi) complications while on aspirin therapy due to a combination of the following: smoking; concurrent nsaid, steroid, clopidogrel, or warfarin therapy; history of upper gi complications; history of renal impairment; history of elevated serum creatinine; hypertension; and cardiac failure. * individuals with cases of allergy or asthma, intolerance, and recurrent vascular events. * individuals taking statins. * individuals who are currently taking aspiring regularly.

Keywords: vascular function inflammation oxidative stress hemostatic balance aspirin firefighting
intraoperative conversion during video-assisted thoracoscopy resection for lung cancer does not alter survival

Conditions: Video-assisted Thoracoscopic Surgery; Lung Cancer; Lobectomy; Survival; Surgery

Summary: anatomical resection with systematic lymph-node dissection is currently the standard of care for the treatment of early stage non-small cell lung cancer. the use of minimally invasive approaches has increased greatly over the last two decades \[either video-assisted thoracoscopic surgery (vats) or robotic-assisted thoracoscopic surgery (rats)\], as they provide the patient with better outcomes than open thoracotomy. minimally invasive vats lobectomy for a standard case is generally a straightforward procedure for a well-trained surgical team, although concomitant preoperative pathologies or intraoperative findings/adverse events may result in technical difficulties, leading to intraoperative conversion, commonly by thoracotomy. the investigators aimed to assess long-term outcomes in a consecutive cohort of patients treated by anatomical pulmonary resection either using vats, vats requiring intraoperative conversion to thoracotomy, or upfront open thoracotomy for lung-cancer surgery.


Eligibility criteria:
inclusion criteria: * all consecutive patients treated by anatomical lobar pulmonary resection (lobectomy, bilobectomy) or anatomical sublobar pulmonary resection (segmentectomy) for non-small cell lung cancer (nsclc), either by vats (eventually with intraoperative conversion) or upfront thoracotomy. exclusion criteria: * patients with non-anatomical pulmonary resection (wedge resection) * patients with a histology other than nsclc (benign or metastatic from another primitive cancer), stage iv nsclc disease, * patients with multiple primary nsclc (synchronous or metachronous) * patients with incomplete resection (r+) * patient for whom a vats approach was never considered

Keywords: video-assisted thoracoscopic surgery lung-cancer surgery intraoperative conversion to open surgery lobectomy survival